RxDoctor Payments Data

Oluwateniola Brown, MD

Urogynecology and Reconstructive Pelvic Surgery · Chicago, ILNPI 1609294438

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,748 of the $3,743 with a category attached, or 73.4%. 6 manufacturers reported payments, led by Medtronic at 43.2% of the total. 2025 is the largest year on record at $3,102, more than ten times the $77 reported in 2019.

$3,743in general payments, 2019–2025

Across 24 payments — averaging $155.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$1K
  • Olympus Winter & Ibe GmbH$850
  • AbbVie$110
  • Axonics, Inc.$48
  • Coloplast$42

What the payments were for

  • Consulting fees$2,74873%
  • Food & beverage$99627%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic6$1,618
Boston Scientific10$1,075
Olympus Winter & Ibe GmbH1$850
AbbVie4$110
Axonics, Inc.2$48
Coloplast1$42

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,743 in reported general payments places this provider in the 55th percentile of 62 urogynecology and reconstructive pelvic surgery providers in Illinois.

See all urogynecology and reconstructive pelvic surgery providers in Illinois

Medicare billing

Part B allowed, 2024
$308,280
Medicare patients
365
Services billed
12,776

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron32$23,012
GemtesaVibegron35$22,697
Estradiol120$7,520
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst33$358
Cephalexin12$54

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →